2019 年第 8 期 第 14 卷

连花清瘟颗粒联合磷酸奥司他韦胶囊治疗流行性感冒的临床效果研究

Clinical efficacy of Lianhua Qingwen granules combined with oseltamivir phosphate capsule in treatment of influenza

作者：化莉刘双

英文作者：

单位：102206北京大学国际医院呼吸与危重症医学科

英文单位：

关键词：流行性感冒；连花清瘟颗粒；磷酸奥司他韦胶囊

英文关键词：

• 摘要：

• 【摘要】目的    观察连花清瘟颗粒联合磷酸奥司他韦胶囊治疗流行性感冒的临床效果。方法    选择2018年10月至2019年4月北京大学国际医院呼吸与危重症医学科收治的流行性感冒患者102例，完全随机分为观察组及对照组，每组51例。对照组口服磷酸奥司他韦胶囊75 mg/次，2次/d，观察组在对照组基础上再给予连花清瘟颗粒6 g/次，3次/d冲服。2组均治疗5 d。比较2组患者临床疗效、退热时间、咽喉肿痛消失时间、咳嗽消失时间、周身酸痛消失时间和治疗前与治疗72 h后C反应蛋白（CRP）、白细胞介素6（IL-6）、T淋巴细胞亚群（CD+4/CD+8比值）水平，观察药物不良反应发生情况。结果    治疗后，观察组总有效率明显高于对照组［96.1%(49/51)比84.3%(43/51)］，差异有统计学意义（P＜0.05）。观察组退热时间、咽喉肿痛消失时间、咳嗽消失时间、周身酸痛消失时间均明显短于对照组［（24±6）h比（36±5）h、（48±4）h比（68±4）h、（45±4）h比（65±3）h、（26±4）h比（39±4）h］，差异均有统计学意义（均P＜0.05）。治疗前，2组CRP、IL-6、CD+4/CD+8比值水平比较，差异均无统计学意义（均P＞0.05）。治疗72 h后，2组CRP、IL-6水平均明显低于治疗前，且观察组低于对照组［（3.3±2.2）mg/L比（5.5±2.1）mg/L、（47±14）mg/L比（55±16）mg/L］，2组CD+4/CD+8比值水平均明显高于治疗前，且观察组高于对照组［（1.76±0.58）比（1.09±0.41）］，差异均有统计学意义（均P＜0.05）。结论    连花清瘟颗粒联合磷酸奥司他韦胶囊治疗流行性感冒效果良好，可有效改善患者的症状和体征，调节免疫功能，缩短疗程。

• 【Abstract】Objective    To observe the clinical effect of Lianhua Qingwen granules combined with oseltamivir phosphate capsule on influenza. Methods    A total of 102 patients with influenza admitted to Department of Respiratory and Critical Care Medicine, Peking University International Hospital from October 2018 to April 2019 were randomly divided into control group and observation group, with 51 cases in each group．The control group took oseltamivir phosphate capsule 75 mg twice a day. The observation group took oseltamivir phosphate capsule(same dosage as control group) and Lianhua Qingwen granules 6 g three times a day. Both groups were treated for 5 days. Clinical efficacy, defervescence time, throat swelling and pain, cough and body ache disappearance time were recorded. Blood contents of C-reactive protein(CRP), interleukin-6(IL-6) and T lymphocyte subsets(CD+4/CD+8) were detected before and 72 hours after treatment. Adverse drug reactions were observed. Results    The total effective rate in observation group was significantly higher than that in control group［96.1%（49/51） vs 84.3%（43/51）］（P＜0.05）. Defervescence time, throat swelling and pain, cough and body ache disappearance time in observation group were significantly shorter than those in control group［（24±6）h vs （36±5）h, （48±4）h vs （68±4）h, （45±4）h vs （65±3）h, （26±4）h vs （39±4）h］（all P＜0.05）. Before treatment, there was no significant difference in CRP, IL-6 and CD+4/CD+8 between groups(all P＞0.05). After 72 hours of treatment, levels of CRP and IL-6 significantly decreased and CD+4/CD+8 significantly increased in both groups; levels of CRP and IL-6 in observation group were significantly lower［（3.3±2.2）mg/L vs （5.5±2.1）mg/L, （47±14）mg/L vs （55±16）mg/L］ and CD+4/CD+8 was significantly higher than those in control group［（1.76±0.58） vs （1.09±0.41）］（P＜0.05）. Conclusion    Lianhua Qingwen granules combined with oseltamivir phosphate capsule treating influenza can effectively improve clinical symptoms and signs, regulate immune function and shorten the course of medication.